Skip to main content
. 2011 Sep 21;21(3):482–489. doi: 10.1007/s00586-011-2020-2

Table 1.

Patients who underwent G-CSF therapy

Case no. Dose of G-CSF (μg/kg/day) Age (years)/gender Diagnosis Most stenotic level Surgical procedure Time of surgery after G-CSF administration (days) Follow-up period after G-CSF administration (months)
1 5 61/M T-OLF T10–11 PD (T2–3, T9–11) 49 6
2 5 68/M T-OPLL T4–5 PDF (T1–T7) 10 6
3 5 51/M T-OPLL T1–2 PDF (C7–T5) 10 6
4 5 37/M T-OPLL T3–4 PDF (T1–T10) 9 6
5 5 35/M C- and T-OPLL C6–7 PDF (C2–T4) 115 6
6 10 46/M T-OPLL T7–8 PDF (T4–T11) 59 6
7 10 67/M C-OPLL C5–6 NS NS 6
8 10 75/M C-OPLL C3–4 PDF (C2–T1) 49 6
9 10 64/M C-OPLL C3–4 PDF (C2–T1) 41 6
10 10 32/M T-OPLL T7–8 PDF (T4–T12) 29 6
11 10 67/M T-OLF T11–12 PD (T10–12) 33 6
12 10 46/M CSM C5–6 PD (C3–7) 94 6
13 10 66/M CSM C4–5 PD (C3–7) 73 6
14 10 67/M CSM C4–5 PDF (C2–T1) 67 6
15 10 74/M CSM C7–T1 PD (C7–T1) 30 6

M male, T thoracic, OLF ossification of ligamentum flavum, PD posterior decompression, OPLL ossification of the posterior longitudinal ligament, PDF posterior decompression with instrumented fusion, C cervical, NS no surgery